Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma. Methods: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.
CITATION STYLE
Sawalha, Y., & Maddocks, K. (2020). Profile of Polatuzumab vedotin in the treatment of patients with relapsed/refractory non-hodgkin lymphoma: A brief report on the emerging clinical data. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S219449
Mendeley helps you to discover research relevant for your work.